Intraperitoneal Chemotherapy
Authors: ROBERT F. OZOLS
Journal: Annals of Internal Medicine (1984)

Editorials1 July 1984Intraperitoneal ChemotherapyROBERT F. OZOLS, M.D., PH.D., CHARLES E. MYERS, M.D., ROBERT C. YOUNG, M.D.ROBERT F. OZOLS, M.D., PH.D.Search for more papers by this author, CHARLES E. MYERS, M.D.Search for more papers by this author, ROBERT C. YOUNG, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-101-1-118 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptDirect instillation of chemotherapeutic agents into the peritoneal cavity of patients with intra-abdominal malignancies is intended to increase drug levels at the predominant sites of disease, thereby resulting in more cytotoxicity than can be achieved with systemic drug administration. Intraperitoneal chemotherapy has been studied most extensively in ovarian cancer, a disease that remains largely confined to the abdominal cavity throughout its course. In early studies a small volume of drug was directly injected into the peritoneal cavity to control malignant ascites. Recent clinical trials have used a large volume of drug (approximately 2 L) to ensure uniform drug distribution throughout...References1. DEDRICKMYERSBUNGAYDEVITA RCPV. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62:1-11. MedlineGoogle Scholar2. OZOLSYOUNG RR. Patterns of failure of gynecologic malignancy: implications for future clinical trials. Cancer Treat Symp. 1983;2:23-4. Google Scholar3. HOWELLPFEIFLEOLSHEN SCR. Intraperitoneal chemotherapy with melphalan. Ann Intern Med. 1984;101:14-8. LinkGoogle Scholar4. JONESCOLLINSMYERS RJC. High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer. Cancer Res. 1981;41:55-9. MedlineGoogle Scholar5. HOWELLCHUWUNGMETHAMENDELSOHN SBWBJ. Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions. J Clin Invest. 1981;67:1161-70. CrossrefMedlineGoogle Scholar6. SPEYERCOLLINSDEDRICK JJR. Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res. 1980;40:567-72. MedlineGoogle Scholar7. GYVESENSMINGERSTETSON JWP. Constant intraperitoneal 5-fluorouracil infusion through a totally implanted system. Clin Pharmacol Thera. 1984;35:83-9. CrossrefMedlineGoogle Scholar8. OZOLSYOUNGSPEYER RRJ. Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res. 1982;42:4265-9. MedlineGoogle Scholar9. HOWELLPFEIFLEWUNG SCW. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med. 1982;97:845-51. LinkGoogle Scholar10. CASPERKELSENALCOCKLEWIS EDNJ. ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the iv route. Cancer Treat Rep. 1983;67:235-8. MedlineGoogle Scholar11. PRETORIUSHACKERBEREK RNJ. Pharmacokinetics of ip cisplatin in refractory ovarian carcinoma. Cancer Treat Rep. 1983;67:1085-92. MedlineGoogle Scholar12. JENKINSSUGARBAKERGIANOLAMYERS JPFC. Technical considerations in the use of intraperitoneal chemotherapy administered by Tenckhoff catheter. Surg Gynecol Obstet. 1982;154:858-62. MedlineGoogle Scholar13. DUNNICKJONESDOPPMANSPEYERMYERS NRJJC. Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamics. AJR. 1979;133:221-3. CrossrefMedlineGoogle Scholar14. OZOLSLOCKERDOROSHOWGROTZINGERMYERSYOUNG RGJKCR. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res. 1979;39:3209-14. MedlineGoogle Scholar15. OZOLSCORDENJACOBWESLEYOSTCHEGAYOUNG RBJMYR. High-dose cisplatin in hypertonic saline. Ann Intern Med. 1984;100:19-24. LinkGoogle Scholar16. ALBERTSCHENSALMON DHS. Chemotherapy of ovarian cancer directed by the human tumor stem cell assay. Cancer Chemother Pharmacol. 1981;6:279-85. CrossrefMedlineGoogle Scholar17. OZOLSWILLSONWELTZGROTZINGERMYERSYOUNG RJMKCR. Inhibition of human ovarian cancer colony formation by adriamycin and its major metabolites. Cancer Res. 1980;40:4109-12. MedlineGoogle Scholar18. YOUNGCANELLOSCHABNERSCHEINHUBBARDDEVITA RGBPSV. Chemotherapy of advanced ovarian carcinoma: a prospective randomized comparison of phenylalanine mustard and high dose cyclophosphamide. Gynecol Oncol. 1974;2:489-97. CrossrefMedlineGoogle Scholar19. OZOLSSPEYERJENKINSMYERS RJJC. Phase II trial of 5-fluorouracil administered intraperitoneally to patients with refractory ovarian cancer. Cancer Treat Rep. 1984. (In press). MedlineGoogle Scholar20. OZOLSMYERSYOUNG RCR. The potential role of anthracyclines in the intraperitoneal chemotherapy of ovarian cancer. In: HANSEN HH ed. Anthracyclines and Cancer Therapy. Amsterdam: Excerpta Medica; 1983:158-65. Google Scholar21. MALCOLMHAINSWORTHJOHNSON AJD. Advanced minimal residual ovarian carcinoma: abdominopelvic irradiation following combination chemotherapy [Abstract]. Proc Am Soc Clin Oncol. 1983;2:151. Google Scholar22. MARKMANGREENPFEIFLE MMC. Combination intracavitary chemotherapy in patients with stage III-IV ovarian carcinoma failing standard treatment regimens [Abstract]. Proc Am Soc Clin Oncol. 1983;2:147. Google Scholar23. YOUNGHOWSERMYERS RDC. Combination chemotherapy (CHex-UP) with intraperitoneal maintenance in advanced ovarian adenocarcinoma [Abstract]. Pro Am Soc Clin Oncol. 1981;22:465. Google Scholar24. BASTBEREKOBRIST RJR. Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum. Cancer Res. 1983;43:1395-401. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Medicine and Clinical Pharmacologic Branches Division of Cancer Treatment National Cancer Institute Bethesda, Maryland PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByFirst line immunochemotherapy with cisplatin-based protocol by intraperitoneal and intravenous routes in ovarian cancer: technique and results of 82 casesLiposomes in the treatment of malignancy: a clinical perspectivePhotodynamic therapy of the canine peritoneum: Normal tissue response to intraperitoneal and intravenous photofrin followed by 630 nm lightChemotherapy by the intravenous and intraperitoneal routes combined in ovarian cancerA phase I/II study of intraperitoneally administered doxorubicin entrapped in cardiolipin liposomes in patients with ovarian cancerProblems of peritoneal access in intraperitoneal treatment and monitoring of ovarian cancerIntraperitoneal Chemotherapy and ImmunotherapyOvarian cancerIntraperitoneal “Belly Bath” ChemotherapyIntraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavityPharmacokinetics and efficacy of i.v. and i.p. VM26 chemotherapy in mice bearing krebs II ascitic tumorsEffektivere Behandlung der Peritonealkarzinose durch intraperitoneale Cis-Diamindichloroplatin (c-DDP)-Gabe mit systemischer NatriumthiosulfatprotektionCatheter complications associated with intraperitoneal chemotherapyOvarian Cancer: New Therapeutic Concepts, Renewed OptimismFRANCO M. MUGGIA, M.D., MARTINE J. PICCART, M.D., JAMES L. SPEYER, M.D. 1 July 1984Volume 101, Issue 1Page: 118-120KeywordsAscitesChemotherapeutic agentsChemotherapyClinical trialsDrug administrationDrug distributionDrug regulationDrugsOvarian cancerSystemic diseases Issue Published: 1 July 1984 PDF DownloadLoading ...